| Line Item | Jun 30, 2026 | Mar 31, 2026 | Jun 30, 2025 | Mar 31, 2025 |
|---|---|---|---|---|
| Net sales | ||||
| Operating expenses: | ||||
| Cost of sales | ||||
| Selling, general and administrative | ||||
| Amortization | ||||
| Restructuring (Note 9) | ||||
| Separation costs | ||||
| Total operating expenses | ||||
| % of revenue | 91.9% | 96.7% | ||
| Operating income | ||||
| % of revenue | 8.1% | 3.3% | ||
| Interest expense | ||||
| Other expense, net (Note 18) | ||||
| Income before income taxes and equity income | ||||
| Income tax expense (Note 13) | ||||
| Income before equity income | ||||
| Equity income, net of tax | ||||
| Net income | ||||
| % of revenue | 4.7% | 3.7% | ||
| Net (loss) income attributable to noncontrolling interest | ||||
| Net income attributable to Versigent | ||||
| % of revenue | 4.8% | 3.5% | ||
| Basic earnings per share attributable to Versigent (in usd per share) | — | |||
| Diluted earnings per share attributable to Versigent (in usd per share) | — |